Danaher (NYSE:DHR) Price Target Cut to $300.00 by Analysts at JPMorgan Chase & Co.

Danaher (NYSE:DHR) had its price objective decreased by JPMorgan Chase & Co. from $310.00 to $300.00 in a research note published on Tuesday morning. JPMorgan Chase & Co. currently has an overweight rating on the conglomerate’s stock.

Several other research firms have also issued reports on DHR. Stephens reiterated an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a report on Thursday, October 31st. Royal Bank of Canada reduced their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Citigroup dropped their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Finally, Evercore ISI raised their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Six equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $285.81.

Danaher Stock Down 1.1 %

Shares of Danaher stock opened at $247.77 on Tuesday. Danaher has a 1 year low of $225.42 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a 50-day moving average of $235.75 and a 200 day moving average of $253.65. The firm has a market cap of $178.96 billion, a price-to-earnings ratio of 47.29, a PEG ratio of 4.43 and a beta of 0.83.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is currently 20.61%.

Institutional Trading of Danaher

Large investors have recently added to or reduced their stakes in the business. FMR LLC boosted its stake in shares of Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares in the last quarter. International Assets Investment Management LLC grew its holdings in Danaher by 40,196.5% during the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after purchasing an additional 428,897 shares during the period. Montrusco Bolton Investments Inc. increased its position in Danaher by 30.4% in the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after buying an additional 397,671 shares in the last quarter. Finally, Union Bancaire Privee UBP SA bought a new position in shares of Danaher in the fourth quarter worth about $74,551,000. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.